Skip to main content

Dapagliflozin and the initial glomerular filtration rate decline in advanced-stage non-diabetic chronic kidney disease

This is a preview of subscription content, access via your institution.

Fig. 1

Availability of data and materials

All data supporting our findings are contained within the manuscript.


  1. Fernandez-Fernandez B, Sarafidis P, Kanbay M, Navarro-González JF, Soler MJ, Górriz JL, Ortiz A. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. Clin Kidney J. 2020;13(5):728–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC. DAPA-CKD trial committees and investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.

    Article  CAS  PubMed  Google Scholar 

  3. Heerspink HJL, Cherney D, Postmus D, Stefánsson BV, Chertow GM, Dwyer JP, Greene T, Kosiborod M, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Toto RD, Wheeler DC. DAPA-CKD Trial committees and investigators. A pre-specified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney Int. 2022;101(1):174–84.

    Article  CAS  PubMed  Google Scholar 

Download references



Author information

Authors and Affiliations



KM, HU, and NT designed the study, collected clinical information, and wrote the manuscript. The final manuscript was approved by all authors.

Corresponding author

Correspondence to Nobuo Tsuboi.

Ethics declarations

Conflict of interest

All authors have nothing to disclose.

Ethical approval

This study was approved by the ethics review board of the Jikei University School of Medicine [34–056 (11201)] and conducted according to the Declaration of Helsinki.

Informed consent

Dapagliflozin is approved by the Ministry of Health, Labour and Welfare in Japan and can be used in daily clinical practice, regardless of the CKD stage. Since this was a retrospective observational study, informed consent from the subjects was not required. In addition, the need for written informed consent has been waived in accordance with the Institutional Review Board of the Jikei University School of Medicine and the “Ethical Guidelines for Research on Medicine and Medical Technology Involving Human Subjects”.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 26 KB)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Matsumoto, K., Ueda, H., Tsuboi, N. et al. Dapagliflozin and the initial glomerular filtration rate decline in advanced-stage non-diabetic chronic kidney disease. Clin Exp Nephrol 26, 1242–1243 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: